PATHOLOGIC STAGE I CUTANEOUS MERKEL CELL CARCINOMA AJCC V8

Clinical trials for PATHOLOGIC STAGE I CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.

Never miss a new study

Get alerted when new PATHOLOGIC STAGE I CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear

Sign up with your email to follow new studies for PATHOLOGIC STAGE I CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Major trial tests if Immune-Boosting drug can stop rare skin cancer from coming back

Disease control Ongoing

This study is testing whether a drug called pembrolizumab can help prevent Merkel cell carcinoma from returning after surgery. It compares the drug against standard monitoring in 280 patients whose cancer was completely removed. The goal is to see if this immunotherapy helps the …

Matched conditions: PATHOLOGIC STAGE I CUTANEOUS MERKEL CELL CARCINOMA AJCC V8

Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

PATHOLOGIC STAGE I CUTANEOUS MERKEL CELL CARCINOMA AJCC V8

Get alerted when new PATHOLOGIC STAGE I CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear

Major trial tests if Immune-Boosting drug can stop rare skin cancer from coming back